NCT01846325

Brief Summary

Since docosahexaenoic acid (DHA) level in sperm membrane has been shown to be decreased in asthenozoospermic men, the investigators hypothesized that DHA supplementation may improve it. Furthermore, the investigators added vitamin E to it to protect its unsaturated bonds which are susceptible to oxidation and production of free oxygen radicals.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
180

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Dec 2013

Shorter than P25 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 1, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 3, 2013

Completed
7 months until next milestone

Study Start

First participant enrolled

December 1, 2013

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

June 16, 2015

Status Verified

June 1, 2015

Enrollment Period

1.2 years

First QC Date

May 1, 2013

Last Update Submit

June 14, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • sperm motility

    spermatogram

    12 weeks

Secondary Outcomes (2)

  • sperm count

    12 weeks

  • seminal oxidative stress

    12 weeks

Study Arms (4)

DHA plus vitamin E

EXPERIMENTAL

Cap DHA 460mg plus vitamin E 600mg per day

Dietary Supplement: vitamin EDietary Supplement: DHA

VitaminE plus placebo

ACTIVE COMPARATOR

vitamin E 600 mg plus placebo

Dietary Supplement: vitamin EOther: placebo

placebo plus placebo

PLACEBO COMPARATOR

DHA shaped placebo plus vitamin E shaped placebo

Other: placebo

DHA plus placebo

ACTIVE COMPARATOR

460 mg DHA plus placebo

Dietary Supplement: DHAOther: placebo

Interventions

vitamin EDIETARY_SUPPLEMENT
DHA plus vitamin EVitaminE plus placebo
DHADIETARY_SUPPLEMENT
DHA plus placeboDHA plus vitamin E
placeboOTHER
DHA plus placeboVitaminE plus placeboplacebo plus placebo

Eligibility Criteria

Age20 Years - 45 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Willing to participate in the study and filling out the informed consent form
  • should be infertile (no conception after 12 months intercourse without any contraception)
  • age 20-45 y.o, idiopathic asthenospermia according to WHO criteria
  • normal hormonal profile

You may not qualify if:

  • any infection in genitourinary (GU) tract
  • any anatomical abnormality in GU tract
  • any chronic disease during last 3 months
  • any surgery in GU tract
  • consumption of omega-3 fatty acids and/or vitamin E supplements during last 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Eslamian G, Amirjannati N, Noori N, Sadeghi MR, Hekmatdoost A. Effects of coadministration of DHA and vitamin E on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. Am J Clin Nutr. 2020 Sep 1;112(3):707-719. doi: 10.1093/ajcn/nqaa124.

MeSH Terms

Conditions

Asthenozoospermia

Interventions

Vitamin E

Condition Hierarchy (Ancestors)

Infertility, MaleGenital Diseases, MaleGenital DiseasesUrogenital DiseasesInfertilityMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

BenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

May 1, 2013

First Posted

May 3, 2013

Study Start

December 1, 2013

Primary Completion

February 1, 2015

Study Completion

May 1, 2015

Last Updated

June 16, 2015

Record last verified: 2015-06